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OBJECTIVE—In mammals, proper storage and distribution of
lipids in and between tissues is essential for the maintenance of
energy homeostasis. In contrast, aberrantly high levels of triglyc-
erides in the blood (“hypertriglyceridemia”) represent a hallmark
of the metabolic syndrome and type 2 diabetes. As hypertriglyc-
eridemia has been identiﬁed as an important risk factor for
cardiovascular complications, in this study we aimed to identify
molecular mechanisms in aberrant triglyceride elevation under
these conditions.
RESEARCH DESIGN AND METHODS—To determine the
importance of hepatic lipid handling for systemic dyslipidemia,
we proﬁled the expression patterns of various hepatic lipid
transporters and receptors under healthy and type 2 diabetic
conditions. A differentially expressed lipoprotein receptor was
functionally characterized by generating acute, liver-speciﬁc
loss- and gain-of-function animal models.
RESULTS—We show that the hepatic expression of lipid trans-
porter lipolysis-stimulated lipoprotein receptor (LSR) is speciﬁ-
cally impaired in mouse models of obesity and type 2 diabetes
and can be restored by leptin replacement. Experimental imita-
tion of this pathophysiological situation by liver-speciﬁc knock-
down of LSR promotes hypertriglyceridemia and elevated
apolipoprotein (Apo)B and E serum levels in lean wild-type and
ApoE knockout mice. In contrast, genetic restoration of LSR
expression in obese animals to wild-type levels improves serum
triglyceride levels and serum proﬁles in these mice.
CONCLUSIONS—The dysregulation of hepatic LSR under
obese and diabetic conditions may provide a molecular rationale
for systemic dyslipidemia in type 2 diabetes and the metabolic
syndrome and represent a novel target for alternative treatment
strategies in these patients. Diabetes 58:1040–1049, 2009
A
ccording to recent estimates, obesity-related
type 2 diabetes will be diagnosed in 200–300
million people worldwide in 2010 (1). As part of
the so-called metabolic syndrome, chronic hy-
perglycemia and dyslipidemia represent major causes for
vascular complications in type 2 diabetic patients and
result from defects in endocrine control systems that
under normal conditions strictly balance glucose and lipid
homeostasis within narrow limits (2).
Dyslipidemia, as associated with diabetic metabolism
and the metabolic syndrome, is characterized by a so-
called proatherogenic blood lipid proﬁle, comprising low
levels of HDLs, increased LDLs, and strongly increased
levels of serum triglycerides associated with VLDLs. In-
deed, hepatic VLDL release is increased in diabetes and is
thought to drive other aspects of the dyslipidemia associ-
ated with this disorder (3). In fact, hypertriglyceridemia is
considered to represent an important risk factor for ath-
erosclerosis and subsequent cardiovascular complications
in type 2 diabetic patients (4).
The regulation of plasma triglyceride levels is conferred
through a complex interplay between different tissues and
cell types (5). Dietary triglycerides within chylomicrons
are hydrolyzed by adipose tissue and skeletal muscle
lipoprotein lipase (LPL), effectively delivering free fatty
acids to these peripheral tissues. The remaining particles,
chylomicron remnants, are subsequently internalized by
the liver. In addition to chylomicron-derived remnant
particles, triglyceride-rich VLDLs are converted to rem-
nants and returned to the liver. Although the ultimate fate
of remnant particles has been clearly shown to be medi-
ated by the liver (6), the identity and relative contribution
of individual receptors involved in this process are still
less clear. The LDL receptor (LDLR), the LDL receptor-
related protein (LRP) 1, and scavenger receptor (SR)-B1
have been found to play only secondary roles in remnant
clearance (7–11). Based on a series of biochemical studies
and effects of whole-body heterozygosity in mice, Bihain
and colleagues suggested that the lipolysis-stimulated re-
ceptor (LSR) serves as a remnant receptor (12–16).
Liver-selective insulin resistance was found to be sufﬁ-
cient to cause hypercholesterolemia and increase the
susceptibility to atherosclerosis (17), suggesting a tight
connection between endocrine control of hepatic metab-
olism and systemic lipid metabolism. It remains unclear to
what extent endocrine circuits control hepatic lipoprotein
receptor expression and/or function, thereby contributing
to the observed dyslipidemia during obesity-related, insu-
lin-resistant type 2 diabetes.
By proﬁling the expression of various lipid transporters
in livers of healthy and diabetic mice under distinct
nutritional conditions, in this study we discovered the
dysregulation of LSR (15) in the liver as a common feature
of various mouse models of obesity-related type 2 diabetes
and demonstrated the importance of hepatic LSR action
for the prevention of hypertriglyceridemia under physio-
logical conditions.
RESEARCH DESIGN AND METHODS
Recombinant adenoviruses. An adenovirus expressing the LSR cDNA and a
corresponding empty cytomegalovirus (CMV) control virus was cloned using
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LSR cDNA was cloned by PCR standard procedures using primers directed
against sequences deposited under GenBank accession number NM_017405.
Adenoviruses expressing LSR-speciﬁc or nonspeciﬁc control oligonucleotides
were produced using the BLOCK-iT Adenoviral RNAi expression system
(Invitrogen) according to the manufacturer’s instructions and puriﬁed by
cesium chloride gradients (18).
Animal experiments. Male 8- to 12-week-old C57BKS, C57BL/6J, db/db,
ob/ob, New Zealand black (NZB), New Zealand obese (NZO), and apolipopro-
tein (Apo)E knockout mice were obtained from Charles River Laboratories
(Brussels, Belgium) and maintained on a 12-h light-dark cycle with unre-
stricted access to food. For starvation experiments, animals were fasted for
24 h with free access to water or fasted and refed for the remaining 6 h. For
virus injections, 1  10
9 plaque-forming units per recombinant virus were
administered via tail vein injection. In each experiment, seven animals
received identical treatments. Mice were killed 7 days after adenovirus
injection in the refed state. Insulin tolerance tests were performed as
described previously (19). In high-fat diet experiments, C57BL6 mice were fed
either a standard laboratory diet (10 energy percentage from fat, D12450B;
Research Diets, New Brunswick, NJ) or a high-fat diet (45 energy percentage
from fat, D12451; Research Diets) for 16 weeks (samples kindly provided by
S. Kersten, Wageningen, Netherlands). Mice carrying a liver-speciﬁc knockout
of the insulin receptor (LIRKO) have been described previously (19) (samples
kindly provided by R. Kulkarni, Boston, MA). To deplete insulin-producing
-cells, C57BL/6J mice were treated with streptozotocin as described (20)
(samples kindly provided by J.C. Bru ¨ning, Cologne, Germany). For leptin
replacement studies, wild-type C57BL/6J and ob/ob mice were daily injected
intraperitoneally with recombinant mouse leptin (5 g/g body weight) (R&D
Systems, Wiesbaden, Germany) for 21 days. Organs including liver, epididymal
fat pads, small intestine, and gastrocnemius muscles were collected after the
corresponding time periods, weighed, snap-frozen, and used for further
mRNA, protein, or metabolic analysis. Total body fat content was determined
by a magnetic resonance imaging body composition analyzer (Echo Medical
Systems, Houston, TX). All animal procedures have been approved by local
authorities and are in accordance with National Institutes of Health
guidelines.
Blood metabolites. Serum levels of glucose, triglycerides, cholesterol,
ketone bodies, and free fatty acids were determined by using an automatic
glucose monitor (One Touch, LifeScan) or commercial kits (Sigma, Munich,
Germany; RANDOX, Crumlin, U.K.; WAKO, Neuss, Germany, respectively).
Hepatic VLDL release. VLDL production was determined after tyloxapol
(Sigma) injection as described (21).
Lipid load tests. For an oral lipid load test, mice were fasted for 16 h and
gavaged with 200 l olive oil. Alternatively, mice were fasted for 16 h, and 100
l of a 2.6% (v/v) intralipid emulsion in saline (Sigma) was administered
intravenously. Serum samples were collected at various time points, and
triglyceride levels were determined by commercial kits as above. Clearance
was calculated by determining the area under the curves for each experimen-
tal group.
Fast protein liquid chromatography. Serum from seven mice per experi-
mental group was pooled and subjected to fast protein liquid chromatography
(FPLC) as described previously (22). Cholesterol and triglyceride levels were
measured in the eluted fractions using commercial kits as above.
Tissue lipid extraction. Hepatic lipids were extracted as described previ-
ously (23), and triglyceride and total cholesterol contents were determined
using commercial kits as above. Values were calculated as micromoles
(triglycerides) or milligrams (cholesterol) per gram frozen tissue.
LPL activity. LPL activity measurements were performed as described (24)
using frozen adipose tissue samples.
Quantitative TaqMan RT-PCR. Total RNA was extracted from homoge-
nized mouse liver using the QIAzol reagent (Qiagen, Hilden, Germany) kit.
cDNA was prepared by reverse transcription using oligo(dT) primer (Fermen-
tas, St. Leon-Rot, Germany). cDNAs were ampliﬁed using assay-on-demand
kits and an ABI PRISM 7700 Sequence detector (Applied Biosystems, Darm-
stadt, Germany). RNA expression data were normalized to levels of TATA
box–binding protein RNA.
Protein analysis. Denatured SDS protein extracts from frozen liver homog-
enates or serum samples were loaded onto an 8% SDS-polyacrylamide gel,
4–12% gradient gels (Invitrogen), and blotted onto nitrocellulose membrane.
Western blot assays were performed as described (25) using antibodies
against valosin-containing protein (VCP) (Abcam, Cambridge, U.K.), ApoB,
ApoE, or ApoAI (Santa Cruz, Heidelberg, Germany) or a mouse monoclonal
antibody generated against the COOH-terminal fragment (amino acids 383–
591) of murine LSR by standard procedures.
RNA interference. Oligonucleotides targeting mouse LSR (GenBank acces-
sion number NM_017405) (5-GCACCTACCAGATGAGCAATA-3) were an-
nealed and cloned into pENTR RNAi vector (Invitrogen). Nonspeciﬁc
oligonucleotides (5-GATCTGATCGACACTGTAATG-3) with no signiﬁcant
homology to any mammalian gene sequence were used as nonsilencing
controls in all experiments.
Cell culture. Primary mouse hepatocytes were isolated and cultured as
described (26). Cells were treated with insulin (100 nmol/l) for 30 min to 24 h
and harvested for mRNA expression analysis.
Statistical analysis. Statistical analyses were performed using a two-way
ANOVA with Bonferroni-adjusted posttests or a t test in one-factorial designs,
respectively. The signiﬁcance level was at P  0.05 or P  0.01.
RESULTS
The importance of hepatic lipid handling for systemic
lipidemia prompted us to proﬁle the expression patterns of
various lipid transporters/receptors under healthy and
diabetic conditions. We analyzed cDNAs from wild-type
C57BKS and db/db diabetic mice (27) under both fasted
and refed conditions using quantitative real-time PCR.
mRNA expression of fatty acid transporter CD36 and fatty
acid transporter (FATP) 4 was induced in diabetic animals
under refed and fasted or fasted conditions only, respec-
tively, whereas FATP 5 was mildly elevated in diabetic
mice in the refed state (Fig. 1A and B). Members of the
ATP-binding cassette (ABC) cholesterol transporter fam-
ily, ABCA1, ABCG1, and ABCG5 as well as bile salt export
pump (BSEP), SR-BI (28), and FATP 3 showed no major
differences in relative gene expression levels between
healthy and diabetic conditions (Fig. 1A and B). ABCA1
and ABCG1 were found to be induced three- to fourfold by
fasting under wild-type and diabetic conditions (Fig. 1A).
Within the group of lipoprotein receptors, expression of
LRP1 was not changed between fasting and refeeding or
under diabetic conditions compared with wild-type con-
trols, respectively (Fig. 1C). In contrast, mRNA expression
of the LDLR was repressed in diabetic animals in the refed
state (Fig. 1C). Furthermore, in the db/db diabetic state
both fasting and refeeding LSR mRNA levels were substan-
tially decreased compared with wild-type control animals
(Fig. 1C), indicating that the loss of this hepatic receptor
represents a speciﬁc feature of diabetic lipid metabolism.
As no liver-speciﬁc loss or gain of function for LSR has
been reported to date, these results prompted us to extend
the analysis of LSR to additional models of type 2 diabetes
and dyslipidemia. Consistent with results from db/db mice,
hepatic LSR mRNA levels were diminished in ob/ob (29) as
well as in NZO mice, the latter representing a multigenic
model for type 2 diabetes (30), compared with correspond-
ing controls (supplementary Fig. 1A and B, available in an
online appendix at http://care.diabetesjournals.org/cgi/
content/full/db08-1184/DC1), and tended to decrease upon
feeding wild-type mice a high-fat diet (supplementary Fig.
1D, left). LSR mRNA levels in the small intestine, a second
major tissue expressing this receptor (31), remained unal-
tered under all conditions (supplementary Fig. 1A and B).
Importantly, the loss of hepatic LSR mRNA expression in
diabetic and obese db/db, ob/ob, and NZO animals was
conﬁrmed at the protein level, as demonstrated by West-
ern blot using a mouse monoclonal antibody against LSR
(Fig. 1D, compare lanes 1–4 with lanes 5–8), whereas
intestinal LSR protein levels were unchanged in these
models (supplementary Fig. 1C).
Insulin plays an important role in hepatic lipid metabo-
lism (32), suggesting that defective insulin signaling could
be responsible for the inhibition of LSR expression in
diabetic mice. LSR mRNA levels were not changed in mice
carrying a liver-speciﬁc knockout of the insulin receptor
(19) or in an insulin-deﬁcient mouse model for type 1
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DIABETES, VOL. 58, MAY 2009 1041FIG. 1. Hepatic LSR expression is repressed in leptin-resistant type 2 diabetes. A–C: Quantitative PCR analysis of cholesterol/bile acid
transporter (A), fatty acid transporter (B), and triglyceride/cholesterol transporter (C) mRNA levels in livers of C57BKS (wild-type [wt]) or
db/db diabetic (db) mice under fasted (24 h) or refed (24 h fasted, 6 h refed) conditions as indicated (n  4) (means  SE). *P < 0.05; **P <
0.01. D: Western blot of liver extracts from four representative wild-type or db/db (upper panel), ob/ob (middle panel), and NZB or NZO (lower
panel) mice under refed conditions using LSR or VCP antibodies. E: Relative changes in body weight in wt and ob/ob mice treated daily with leptin
(5 g/g body weight) for a period of 21 days (means  SE). F: Western blot of liver (upper panel) and intestinal (lower panel) extracts from the
same mice as in E using LSR or VCP antibodies. Two representative animals per group are shown. G: Pearson correlation coefﬁcient shown for
relative hepatic LSR protein levels versus body weight in the same mice as in E. L, leptin; S, saline.
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tary Fig. 1D, middle and right), indicating that insulin per
se is not responsible for the observed inhibition of LSR
expression in the other models. Indeed, insulin treatment
of primary mouse hepatocytes did not inﬂuence LSR
mRNA expression in these cells (data not shown).
In addition to defective insulin signaling, obesity in mice
and humans is characterized by leptin resistance (33,34).
To test the hypothesis that leptin deﬁciency and/or resis-
tance as exempliﬁed by the ob/ob (29) or db/db (27) and
NZO (35) models, respectively, are triggers for LSR inhi-
bition under obese and diabetic conditions, we performed
leptin replacement studies in ob/ob mice as a model for
absolute leptin deﬁciency (29). Daily leptin administration
over a 3-week period substantially reduced food intake
(supplementary Fig. 1E), body weight (Fig. 1E), and
whole-body fat content (supplementary Fig. 1F)i nob/ob
mice. Remarkably, leptin replacement completely restored
hepatic LSR protein expression in ob/ob animals to wild-
type levels (Fig. 1F, upper panel, compare lanes 7–8 with
lanes 1–2), but left intestinal LSR protein levels unaffected
(Fig. 1F, lower panel). Hepatic LSR protein levels corre-
lated signiﬁcantly with body weight in both leptin- and
saline-treated wild-type and ob/ob mice (Fig. 1G), suggest-
ing that functional leptin signaling and action represent
critical signals for the maintenance of hepatic LSR expres-
sion in lean, healthy animals. Together, these results
indicate that the loss of hepatic LSR expression in turn
represents a common feature of obesity-related, leptin-
resistant type 2 diabetes.
To address the potential functional consequences of
hepatic LSR inhibition for the pathophysiological pheno-
type in the above-described diabetes mouse models, we
generated adenoviral constructs expressing LSR-speciﬁc
or nonspeciﬁc small hairpin RNAs (shRNAs) and delivered
these constructs into healthy, wild-type mice via tail vein
injection. As shown in Fig. 2, LSR-speciﬁc shRNA delivery
reduced hepatic LSR expression to 10% of control mRNA
levels and almost completely eliminated hepatic LSR pro-
tein expression, as shown by Western blot analysis (Fig.
2A and B, upper panel). In contrast, no effect of the LSR
shRNA adenovirus on LSR mRNA and protein expression
levels in adipose tissue, skeletal muscle, or small intestine
could be observed (Fig. 2A and B, lower panel). These
experiments validated the previously reported liver spec-
iﬁcity of this gene delivery technology (25) and allowed
the exploration of liver-speciﬁc LSR functions for systemic
metabolism in the absence of potentially confounding
effects of LSR ablation in other tissues, as reported re-
cently (16). Importantly, LSR shRNA adenovirus did not
affect the mRNA and/or protein expression of related
lipoprotein receptors, LDLR, LRP1, and SR-B1 (Fig. 2C and
supplementary Fig. 2A), thereby excluding compensatory
effects of these receptors in response to acute LSR gene
knockdown.
Phenotypic analysis of liver-speciﬁc LSR knockdown
animals demonstrated that the loss of hepatic LSR resulted
in an almost threefold induction of serum triglyceride
levels compared with control littermates and signiﬁcantly
elevated serum total cholesterol already 7 days after
adenovirus delivery (Fig. 2D). In contrast, hepatic triglyc-
eride stores were found to be lowered by 75% upon hepatic
LSR knockdown, and hepatic cholesterol content was also
signiﬁcantly diminished (Fig. 2D). Importantly, these ef-
fects of LSR knockdown were only observed in the refed
state—not under fasting conditions (supplementary Fig.
2B), suggesting that LSR speciﬁcally affects postprandial
lipid homeostasis. LSR deﬁciency had no effect on sys-
temic insulin sensitivity as determined by an insulin toler-
ance test (supplementary Fig. 2C). In addition, body
weight (supplementary Fig. 2D), serum glucose (supple-
mentary Fig. 2E), free fatty acids (FFAs) (supplementary
Fig. 2F), total serum ketone body levels (supplementary
Fig. 2G), whole-body fat content (supplementary Fig. 2H),
and adipose tissue LPL activity (supplementary Fig. 2I)
remained unchanged, showing that hepatic LSR deﬁciency
speciﬁcally determines hepatic and systemic triglyceride
handling. Indeed, liver-speciﬁc LSR knockdown signiﬁ-
cantly delayed systemic triglyceride clearance in an intra-
venous lipid load test and also tended to delay clearance of
an oral lipid load (Fig. 2E and F). In contrast, analysis of
hepatic VLDL secretion rates demonstrated that LSR-
speciﬁc shRNA treatment had no effect on liver VLDL
output compared with that of control littermates (supple-
mentary Fig. 2J), further supporting the notion that he-
patic LSR activity is particularly involved in the clearance
and uptake of circulating serum triglycerides.
We next sought to explore the basis for the observed
hypertriglyceridemia in liver-speciﬁc LSR knockdown an-
imals in more detail. To this end, we performed FPLC
analysis of serum samples from LSR knockdown and
control littermates. Consistent with the induction of total
serum triglyceride levels, LSR deﬁciency promoted a sig-
niﬁcant increase in triglycerides associated with the VLDL/
chylomicron and LDL fractions (Fig. 3A). In addition, LSR
shRNA treatment caused an increase in VLDL/chylomicron
and HDL cholesterol content compared with control
shRNA-treated littermates (Fig. 3B). In accordance with
these proﬁles, the levels of ApoB and ApoE, the major
lipoproteins of VLDL, intermediate-density lipoproteins,
and chylomicrons were increased in serum of liver-speciﬁc
LSR knockdown mice compared with controls, whereas
ApoAI remained unchanged (Fig. 3C). Thus, liver-speciﬁc
LSR deﬁciency produced hypertriglyceridemia with trig-
lyceride-enriched VLDL particles and elevated ApoB/E
serum levels as commonly associated with type 2 diabetes
and the metabolic syndrome.
We aimed to explore the relative importance of ApoB
and ApoE particles for the LSR-mediated effects on sys-
temic triglyceride levels. To this end, we used ApoE
knockout mice (ApoE
/) as a standard model for sys-
temic dyslipidemia and total ApoE deﬁciency (36). Adeno-
viral LSR shRNA delivery efﬁciently inhibited both mRNA
and protein expression of LSR in livers of ApoE
/ mice
(Fig. 4A and B), but left intestinal LSR expression levels
unaffected (Fig. 4A). As shown for wild-type mice before
(Fig. 2), hepatic knockdown of LSR increased total serum
triglyceride levels in ApoE
/ mice by twofold (Fig. 4C)
and lowered hepatic triglyceride stores in these animals
(Fig. 4C). Indeed, FPLC analysis revealed a substantial
increase in the VLDL-related serum triglyceride fraction
upon LSR knockdown in ApoE
/ mice (Fig. 4D), indicat-
ing that LSR exerts its regulatory impact on circulating
triglycerides mainly through the interaction with ApoB
with secondary rises in ApoE in response to hepatic LSR
deﬁciency in wild-type mice (Fig. 2). Consistent with a
speciﬁc effect of LSR on triglyceride metabolism, loss of
hepatic LSR expression produced no effects on body
weight (supplementary Fig. 3A), serum glucose (supple-
mentary Fig. 3B), FFAs (supplementary Fig. 3C), and total
ketone body levels (supplementary Fig. 3D). In addition,
LSR knockdown in ApoE
/ mice slightly inﬂuenced se-
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on liver cholesterol levels (supplementary Fig. 3F)o ro n
apolipoprotein-associated cholesterol serum proﬁles as
determined by FPLC analysis (supplementary Fig. 3G).
These results favored the hypothesis that LSR-depen-
dent ApoB clearance from the circulation counteracts
hypertriglyceridemic dyslipidemia in ApoE
/ mice. To




FIG. 2. Liver-speciﬁc loss of LSR promotes hypertriglyceridemia. A: Quantitative PCR analysis of LSR mRNA levels in livers, white adipose tissue (WAT),
skeletal muscle, and small intestine of C57BL/6J mice injected with control or LSR-speciﬁc shRNA adenovirus at day 7 after virus delivery (n7). B: Western
blot of liver (upper panel) and intestinal (lower panel) extracts from four and two representative control (Ctrl) or LSR shRNA–injected C57BL/6J mice using
LSR or VCP antibodies at day 7 after virus delivery. C: Quantitative PCR analysis of LDLR, LRP1, and SR-B1 mRNA levels in livers of the same mice as in A
(n  7). D: Serum and liver triglyceride (TG) and cholesterol (CHOL) levels in the same mice as in A (n  7). Values are shown for the refed state. E:
Intravenous lipid load test (ILLT) in the same mice as in A. Mice were injected intravenously with 100 l of a 2.6% lipid emulsion and serum triglyceride levels
were followed for 2 h. Average area under the curve (arbitrary units) is shown (n  7) (means  SE). **P < 0.01. F: Oral lipid load test (OLLT) in the same
mice as in A. Mice received an oral load of 200 l olive oil and serum triglyceride levels were followed for 6 h. Average area under the curve (arbitrary units)
is shown (n  7) (means  SE).
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LSR in livers of wild-type or ApoE
/ animals (Fig. 4E and
supplementary Fig. 4A). To this end, LSR adenovirus left
intestinal LSR mRNA and protein levels unaffected (Fig.
4E and supplementary Fig. 4B). In agreement with previ-
ous results (Fig. 2), LSR overexpression did not inﬂuence
body weight (supplementary Fig. 4C), serum glucose (sup-
plementary Fig. 4D), FFAs (supplementary Fig. 4E), total
ketone body levels (supplementary Fig. 4F), or total serum
or liver cholesterol levels and/or serum distribution (sup-
plementary Fig. 4G–I). However, hepatic LSR overexpres-
sion signiﬁcantly decreased serum triglyceride levels in
ApoE
/ mice (Fig. 4F) and substantially reduced VLDL-
associated triglycerides in hyperlipidemic ApoE
/ ani-
mals (Fig. 4G), substantiating the conclusion that LSR
counteracts systemic hypertriglyceridemia via the induc-
tion of ApoB-dependent triglyceride clearance from the
circulation.
Thus far, the data demonstrated that the hepatic triglyc-
eride receptor LSR represents a critical checkpoint for
systemic triglyceride metabolism and that the absence of
LSR in the liver promotes a hypertriglyceridemic shift
toward triglyceride-rich, ApoB/ApoE-containing lipopro-
teins in lean mice. The downregulation of LSR in animals
with obesity-related, leptin-resistant type 2 diabetes (Fig.
1) suggested that the reduction of LSR expression might
contribute to the pathophysiological phenotype of these
animals and promote aberrant triglyceride metabolism
under these conditions.
To ﬁnally test this hypothesis, we delivered the LSR
overexpression adenovirus into ob/ob mice (29). Adenovi-
ral gene delivery restored hepatic expression of LSR in
ob/ob mice to physiological wild-type amounts at mRNA
(Fig. 5A) and protein (Fig. 5B) levels. At day 7 after virus
injection, LSR reconstitution in ob/ob mice had no effects
on body weight (supplementary Fig. 5A), serum glucose
(supplementary Fig. 5B), FFAs (supplementary Fig. 5C),
and total body fat content (supplementary Fig. 5D) com-
pared with control-injected littermates. LSR restoration in
ob/ob livers triggered a signiﬁcant reduction in serum
triglyceride and cholesterol levels (Fig. 5C), again demon-
strating the speciﬁcity of LSR action for hepatic and
systemic lipid metabolism even under obese conditions.
To this end, genetic LSR reconstitution in ob/ob mice
reduced VLDL/chylomicron and LDL triglyceride levels,
while simultaneously decreasing circulating LDL/HDL1
(37) and HDL cholesterol levels in these animals (Fig. 5D).
Interestingly, hepatic triglyceride and cholesterol content
remained unchanged in response to LSR overexpression
(Fig. 5C), suggesting intrahepatic compensation for in-
creased triglyceride uptake. Indeed, correlating with sig-
niﬁcantly increased serum ketone body levels
(supplementary Fig. 5E), mRNA levels of genes in the fatty
acid oxidation pathway but not in the lipogenic program
were found to be induced in LSR-overexpressing ob/ob
mice (supplementary Fig. 5G and H), which was further
associated with an increase in hepatic VLDL release
(supplementary Fig. 5F).
Together, these data indicate that the lipid receptor
(LSR) represents a key checkpoint in hepatic and systemic
triglyceride metabolism. The downregulation of LSR dur-
ing the manifestation of leptin-resistant, obesity-related
type 2 diabetes may contribute to the commonly observed
hypertriglyceridemia in diabetic and obese subjects and
may further aggravate the risk for cardiovascular compli-
cations under these conditions.
DISCUSSION
Detailed molecular mechanisms in the pathogenesis of
clinically severe aberrations in circulating lipid levels as
associated with obesity and type 2 diabetes have not been
completely deﬁned. We identify an unexpected loss of
function of the remnant lipoprotein receptor (LSR) as a
common feature of obesity-related type 2 diabetic condi-
tions in mouse models.
LSR has been initially found to be involved in the
degradation of LDL in ﬁbroblasts from a subject homozy-
gous for familial hypercholesterolemia and lacking the
LDLR (38). Genetic inactivation of the LSR gene leads to
embryonic lethality (31), and studies on phenotypic con-
sequences of whole-body LSR heterozygosity demon-
strated effects on systemic triglyceride metabolism (16).
Although extrahepatic functions of LSR remain unclear,
FIG. 3. Hepatic LSR deﬁciency speciﬁcally affects VLDL triglyceride
(TG) and ApoB/E levels. A: Triglyceride content of serum fractions
from control (Ctrl) or LSR shRNA–injected C57BL/6J mice at day 7
after injection. Serum pools of n  7 animals per group were separated
by FPLC. Individual fraction numbers are indicated. B: Cholesterol
(CHOL) content of serum fractions from the same mice as in A. C:
Western blot of serum samples from two representative control or LSR
shRNA–injected C57BL/6J mice using ApoB, ApoE, or ApoAI antibodies
at day 7 after virus delivery. Chylo, chylomicrons; IDL, intermediate-
density lipoprotein.
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function of LSR in the liver. Our functional analysis of
liver-speciﬁc LSR deﬁciency suggests that LSR plays a
critical role in the clearance of triglyceride-rich, ApoB-
containing VLDL particles, especially in the postprandial
phase (Fig. 2), as loss of LSR function in both wild-type
and ApoE
/ mice promoted the occurrence of an aber-
rant blood lipid proﬁle with high serum triglyceride and
ApoB/ApoE levels (Figs. 2 and 3). The fact that our
liver-speciﬁc LSR knockdown displayed a more severe
triglyceride phenotype than the hypertriglyceridemia in
LSR heterozygous mice (16) indicates that the liver indeed
represents the major site of LSR action. This is supported
by the absence of changes in intestinal LSR expression
levels in diabetes models (Fig. 1) as well as by the liver
LSR-dependent clearance of intravenous lipid challenges
(Fig. 2F). In line with these in vivo data, cellular studies in
isolated hepatocytes have shown an important role of LSR
in ApoB/E-containing lipoprotein uptake in vitro
(12,16,39), its high afﬁnity for triglyceride-rich lipopro-
FIG. 4. Hepatic LSR controls triglyceride (TG) levels in ApoE
/ mice. A: Quantitative PCR analysis of LSR mRNA levels in livers and small
intestine of ApoE
/ mice injected with control (Ctrl) or LSR-speciﬁc shRNA adenovirus at day 7 after virus delivery (n  7) (means  SE). **P <
0.01. B: Western blot of liver extracts from four representative control or LSR shRNA–injected ApoE
/ mice using LSR or VCP antibodies at day
7 after virus delivery. C: Serum and liver triglyceride levels in the same mice as in A (n  7) (means  SE). *P < 0.05; **P < 0.01. D: Triglyceride
content of serum fractions from control or LSR shRNA–injected ApoE
/ mice at day 7 after injection. Serum pools of n  7 animals per group
were separated by FPLC. Individual fraction numbers indicated. Chylo, chylomicrons; IDL, intermediate-density lipoprotein. E: Western blot of
liver (upper panel) and intestinal (lower panel) extracts from two representative wild-type (wt) and ApoE knockout (ApoE
/) mice injected
with control (Ad-CMV) or LSR overexpression (Ad-LSR) adenovirus, respectively, using LSR or VCP antibodies at day 7 after virus delivery. F:
Serum and liver triglyceride levels in the same mice as in E (n  7) (means  SE). *P < 0.05; **P < 0.01. G: Triglyceride content of serum fractions
from the same mice as in E. Serum pools of n  7 animals per group were separated by FPLC. Individual fraction numbers are indicated.
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speculate that the observed hypertriglyceridemia in Apo-
CIII transgenic mice (at least in part) can be explained by
its inhibitory effect on LSR function (40).
In addition to ApoB-containing remnant clearance, ele-
vated HDL cholesterol along with unaltered ApoAI (Fig.
2G and H) levels and signiﬁcantly reduced HDL choles-
terol in LSR-overexpressing ob/ob mice (Fig. 5D) imply a
role of LSR also in the clearance of HDL cholesterol.
Indeed, similar effects have been observed in mice deﬁ-
cient in the HDL receptor, SR-BI (28), and overexpression
of SR-BI results in reduced plasma concentrations of HDL
cholesterol (41). Whether the mechanisms of clearance of
triglyceride-rich lipoproteins and a potential role of LSR in
reverse cholesterol uptake are regulated by a common
upstream signal needs to be further investigated.
This study provides evidence for a unique and speciﬁc
role of hepatic LSR in systemic lipid homeostasis. Our
pharmacological and genetic reconstitution studies dem-
onstrate that liver-speciﬁc restoration of LSR is sufﬁcient
to improve VLDL triglyceride levels in obese and ApoE
/
mice, promoting the notion that the inhibition of LSR
expression in liver represents a critical determinant of
pathophysiological lipid homeostasis in obesity-related
type 2 diabetes. Indeed, leptin resistance as frequently
observed under these conditions (33,34) seems to provide
the endocrine explanation for the downregulation of LSR
during obesity and/or weight gain (Fig. 1F–H) as long-term
restoration of functional leptin signaling is sufﬁcient to
maintain hepatic LSR levels, thereby correlating with
improved body weight (Fig. 1G). Further studies will be
necessary to clarify the role of LSR as a molecular
FIG. 5. Hepatic LSR restoration lowers serum triglyceride (TG) in obese mice. A: Quantitative PCR analysis of LSR mRNA levels in livers
of C57BL/6J and ob/ob mice injected with control (Ad-CMV) or LSR-expressing (Ad-LSR) adenovirus at day 7 after virus delivery (n  7)
(means  SE). *P < 0.05. B: Western blot of liver extracts from two representative control (Ad-CMV) or LSR expressing (Ad-LSR)
adenovirus–injected C57BL/6J and ob/ob mice using LSR or VCP antibodies at day 7 after virus delivery. Labels indicate Flag-tagged LSR
expression by adenovirus delivery, comigrating with the endogenous 68-kDa LSR subunit, and endogenous LSR levels representing the
56-kDa subunit in mice receiving control virus. C: Serum and liver triglyceride and cholesterol (CHOL) levels in ob/ob mice as in A and B,
injected with control (Ad-CMV) or LSR-expressing (Ad-LSR) adenovirus (n  7) (means  SE). *P < 0.05. D: Triglyceride (upper panel)
and cholesterol (lower panel) content of serum fractions from the same mice as in C. Serum pools of n  7 animals per group were separated
by FPLC. Individual fraction numbers are indicated. Chylo, chylomicrons.
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such as cardiovascular damage and atherosclerosis. In this
regard, the development of compounds that speciﬁcally
modulate LSR function in the liver may provide useful
adjunct antidyslipidemic therapy for patients with obesity
and type 2 diabetes.
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